Completed PHASE1 INTERVENTIONAL 3-arm NCT04330664

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2

Sponsor: Mirati Therapeutics Inc.

Conditions Advanced Cancer Malignant Neoplastic Disease Metastatic Cancer

Interventions MRTX849 TNO155

Updated 17 times since 2020 Last updated: Apr 3, 2025 Started: Apr 7, 2020 Primary completion: Jul 29, 2022 Completion: Feb 24, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04330664, this PHASE1 trial focuses on Advanced Cancer and Malignant Neoplastic Disease and remains completed. Sponsored by Mirati Therapeutics Inc., it has been updated 17 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
May 2025 — Sep 2025 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Mar 2025 — May 2025 [monthly]

Active Not Recruiting PHASE1
Jan 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE1

Phase: PHASE1/PHASE2 → PHASE1

▶ Show 12 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2021 — Apr 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE1_PHASE2
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE1_PHASE2
Jun 2020 — Sep 2020 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
May 2020 — Jun 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mirati Therapeutics Inc.
Novartis

Data source: Mirati Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chicago, United States , City of Saint Peters, United States , Creve Coeur, United States , Los Angeles, United States , Milwaukee, United States , New York, United States , Novi, United States , Orange, United States , San Antonio, United States and 2 more locations